After slashing its yearly revenue prediction, Dexcom's stock price plummets.
Shares of medical device maker Dexcom fell 40% in extended trading after the company slashed its yearly revenue projection on Thursday, citing a reorganization of its sales force, fewer customers, and reduced revenue per customer as reasons. After previously projecting $4.20–4.35 billion in sales for 2024, the business now anticipates $4–4.05 billion. The average expectation... Read more